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ABSTRACT
WRN protein loss causes Werner syndrome (WS),
which is characterized by premature aging as
well as genomic and telomeric instability. WRN
prevents telomere loss, but the telomeric protein
complex must regulate WRN activities to prevent
aberrant telomere processing. Telomere-binding
TRF2 protein inhibits telomere t-loop deletion by
blocking Holliday junction (HJ) resolvase cleavage
activity, but whether TRF2 also modulates HJ dis-
placement at t-loops is unknown. In this study, we
used multiplex fluorophore imaging to track the
fate of individual strands of HJ substrates. We
report the novel finding that TRF2 inhibits WRN
helicase strand displacement of HJs with telomeric
repeats in duplex arms, but unwinding of HJs with
a telomeric center or lacking telomeric sequence is
unaffected. These data, together with results using
TRF2 fragments and TRF2 HJ binding assays,
indicate that both the TRF2 B- and Myb domains
are required to inhibit WRN HJ activity. We
propose a novel model whereby simultaneous
binding of the TRF2 B-domain to the HJ core and
the Myb domain to telomeric arms promote and
stabilize HJs in a stacked arm conformation that is
unfavorable for unwinding. Our biochemical study
provides a mechanistic basis for the cellular
findings that TRF2 regulates WRN activity at
telomeres.
INTRODUCTION
Lack of the Werner protein (WRN) causes Werner
syndrome (WS), a segmental progeroid disorder char-
acterized by cellular genomic and telomeric instability
and premature senescence (1,2). WRN is a RecQ family
helicase that is unique among the ﬁve human RecQ
helicases for also having an exonuclease domain (3).
Many of the RecQ helicases, in general, are thought to
function during DNA replication to prevent replication
fork demise and to restore stalled or broken replication
forks, partly through homologous recombination (HR)
pathways (4). Consistent with this, WRN protein is
implicated in pathways for recombinational repair of
stalled replication forks and DNA double-strand breaks
(5,6). WRN is proposed to have particularly impor-
tant roles in telomere preservation during replication.
Telomeres protect chromosomes ends, and telomere dys-
function triggers cellular senescence, apoptosis or genomic
instability (7). The forced expression of telomerase in WS
ﬁbroblasts suppresses many of the primary cellular
defects, including telomere loss on sister chromatids (8),
premature senescence (9) and the accumulation of chro-
mosomal aberrations (10). Cellular and biochemical data
indicate that WRN may preserve telomeres by dissociating
alternate DNA structures to facilitate replication fork
progression or for completion of HR repair at stalled or
broken replication forks (2). These DNA structures
include G-quadruplexes, four-way junctions that mimic
regressed replication forks and Holliday Junction (HJ)
intermediates in HR, and D-loop structures that occur
during HR and at the telomeric end (11,12). All of these
are preferred substrates for WRN helicase which can also
branch migrate HJ and D-loops (12,13). These studies
suggest that inappropriate processing of alternate struc-
tures at telomeres can lead to premature telomere loss
and cell senescence or apoptosis.
Human telomeres are characterized by repetitions of a
short sequence of duplex DNA (TTAGGG) and a
30 overhang of single-stranded DNA (ssDNA), bound by
the shelterin complex of six proteins (7,14). The
30 overhang, which may be 50–500nt, is bent around
into a t-loop and then invades the duplex DNA, displacing
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(D-loop) (15). Telomere D-loop formation is thought to
be mechanistically similar to D-loop formation during the
initiation of HR (7,16,17). The shelterin protein TRF2 is
critically important for stimulating formation and preser-
vation of the telomeric t-loop/D-loop structure (18–20).
TRF2 has two DNA-binding domains: an N-terminal
basic domain that binds four-way junctions regardless of
sequence (21) and a C-terminal Myb domain that specif-
ically binds duplex TTAGGG repeats (22). Cellular
studies showed that the overexpression of TRF2 lacking
the B-domain (TRF2B) results in cleavage of the t-loop/
D-loop by HJ resolvase XRCC3 (16), which leads to
extra-chromosomal telomeric circles that can be visualized
by two-dimensional (2-D) electrophoresis and electron
microscopy (16,23). TRF2 binds to and inhibits cleav-
age of four-way junction models of HJ structures
in vitro (21,24). WRN is required for the production
of telomeric circles in TRF2B overexpressed cells (25),
but the mechanism is unknown. Interestingly, in telo-
merase-positive WS cells, telomeric circles form in the
absence of WRN and independently of XRCC3,
implicating WRN in more than one pathway for
telomere stability (25). While TRF2 is known to protect
HJs from cleavage by HJ resolvases (24), whether TRF2
also regulates displacement and migration at the telomere
t-loop/D-loop is not known.
One model for WRN promotion of telomeric circles in
TRF2B expressing cells is that WRN stimulates branch
migration of the t-loop/D-loop into a target for cleavage.
HJ-like structures also form preferentially at telomeres
during replication fork regression that produces a
four-way junction in which one duplex end is accessible
(chicken foot) (26). WRN exonuclease can attack this vul-
nerable end, and the helicase can displace the four-way
junction (27). Both TRF2 and WRN bind the HJ core
in vitro (21,28). Therefore, it is possible that TRF2 may
protect HJs from WRN activity by inhibiting WRN
loading. Paradoxically, TRF2 binds directly to WRN
protein in vivo (25,29,30), and in vitro studies showed
that TRF2 recruits WRN to telomeric substrates (29),
stimulates WRN exonuclease digestion of telomeric
duplexes (29) and stimulates WRN helicase unwinding
of short forks (30). Whether TRF2 modulates WRN pro-
cessing of HJ DNA is not known.
Given that TRF2 represses WRN promotion of t-circles
(25), in this study, we tested the hypothesis that
TRF2 negatively regulates WRN activity on four-way
structures that may occur at the t-loop/D-loop or during
replication fork regression. By testing a variety of
HJ substrates containing site-speciﬁc blocks to WRN
helicase 30–50 translocation, we provide evidence
that WRN displaces four-way structures from the center
moving outward. We also found that TRF2 pro-
tects telomeric HJ DNA against WRN strand displace-
ment activity. However, both the TRF2 B and
Myb DNA-binding domains are required for WRN inhi-
bition, indicating that TRF2 must engage both the HJ
core and the duplex arms to regulate WRN strand
displacement.
MATERIALS AND METHODS
Proteins
Recombinant human hexahistidine-tagged WRN protein
and the exonuclease-dead E84A WRN mutant (X-WRN)
were puriﬁed from a baculovirus/insect cell expression sys-
tem as described previously (31). Recombinant human
hexahistidine-tagged RPA was provided as a gift from
Dr Walter Chazin (Vanderbilt University, TN, USA).
Recombinant human hexahistine-tagged TRF2 protein
was puriﬁed as formerly described (30). Recombinant
hexahistine TRF2 protein fragment (amino acids 45–501;
TRF2B) was generated by polymerase chain
reaction (PCR) cloning using the TRF2 cDNA from the
baculovirus DNA construct, kindly provided by Dr Titia
de Lange (Rockefeller University, New York, NY) as
a template. The PCR product was subcloned into the
BamHI and EcoRI sites of the pRSET-A expression
vector (Invitrogen, Carlsbad, CA). The TRF2B
fragment was expressed in BL21(DE3) Escherichia
coli and puriﬁed with an AKTA Explorer FPLC (GE
Life Sciences, Piscataway, NJ). After the induction
of TRF2B expression with 1mM isopropyl-b-D-
thiogalactoside (IPTG) for 4h at 30 C, cells were har-
vested and resuspended in lysis buﬀer (20mM
NaH2PO4, 0.5M NaCl, 10mM imidazole, 1% NP-40
and 5mM beta-mercaptoethanol) and mixed on a
rotator at 4 C for 30min. Protease inhibitors were
included in all buﬀers (Roche Molecular Biochemicals,
Indianapolis, IN). Cells were centrifuged at 15000r.p.m.
for 30min at 4 C. The supernatant was loaded onto a
HisTrap FF (GE Life Sciences) column equilibrated
with lysis buﬀer. The column was washed with buﬀer A
(20mM NaH2PO4, 0.5M NaCl) containing 10mM
imidazole, and subsequently washed and protein eluted
with 60mM and 100mM imidazole, respectively. The
eluant was dialyzed against buﬀer D (20mM HEPES,
pH 7.9, 100mM KCl, 3mM MgCl2, 1mM DTT, 20%
glycerol, 0.5mM PMSF) in Slide-a-lyzer cassettes
(Thermo Fisher, Rockford, IL, USA) at 4 C. Protein
purity and concentration were determined by SDS
PAGE Coomassie analysis and Bradford assay, respec-
tively. The pGEX4T-RAP1 construct was kindly
provided by Dr Zhou Songyang (Baylor College of
Medicine, Houston, TX). GST-tagged human RAP1 was
expressed in BL21 (DE3) E. coli and puriﬁed on
glutathione Sepharose beads (GE Life Sciences) in batch
followed by Thrombin (GE Healthcare) cleavage as
previously described with some modiﬁcation (32).
Following the induction of RAP1 expression with 1mM
IPTG for 2h at 37 C, cells were harvested at 3800r.p.m.
for 15min at 4 C, resuspended in lysis buﬀer (1X PBS,
protease inhibitors, 50mM beta-mercaptoethanol and
1% Triton X-100), sonicated and mixed in a rotator for
15min at 4 C. Cell lysate was harvested at 10000r.p.m.
for 10min, and the supernatant was incubated
with glutathione-Sepharose beads (GE Healthcare,
Piscataway, NJ) for 3h at 4 C on a rotator. Bound
GST-tagged RAP1 was cleaved with Thrombin (GE
Healthcare) for 12h at 4 C. The supernatant was loaded
onto a Mono Q 5/50 GL (GE Life Sciences) column
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NaCl, 0.05% NP-40 and 10% glycerol). RAP1 protein
was eluted in buﬀer B (150mM Tris pH 8.0, 10%
glycerol and 0.05% NP-40) at 335mM NaCl. Protein
purity and concentration were determined by sodium
dodecyl sulfate polyacrylamide gel electrophoresis,
(SDS–PAGE) Coomassie analysis and Bradford assay,
respectively.
DNA substrates
All oligonucleotides were purchased from Integrated
DNA Technologies (Coralville, IA, USA) and PAGE-
puriﬁed by the manufacturer, except for HJbio-4, which
was purchased from and PAGE-puriﬁed by Gene Link
(Hawthorn, NY, USA). Fluorescent labels were covalently
linked to the 50 nucleotide by the manufacturer. Sequences
are provided in Supplementary Table S1.
All HJ constructs, modiﬁed from the XJ12 described
previously (11) and with the exception of HJT (Table 1),
were annealed in 25ml reaction volumes. For HJ DNA
constructs, 10 or 12pmol of the indicated oligonucleotide
1 was mixed with a 1:2:3:2 molar ratio with the respective
2, 3 and 4 oligonucleotides (Table 1), respectively, in
0.35  PBS and 350mM LiCl. The oligonucleotides were
annealed in a TC-312 PCR machine (Techne, Burlington
NJ) by incubating at 95 C for 5min, followed by cooling
to 65 Ca t1  /min.The reactions were held at 65 C for
5min, cooled to 37 Ca t1  /min, then incubated at 37 C
for 8h and then cooled to 10 C.
The HJT construct was prepared by ﬁrst annealing the
forked halves of the substrate separately in 12.5ml
reactions with 100mM LiCl and 0.5  TE buﬀer: one
with 10pmol T-1 and 20pmol T-2, and the other with
40pmol T-3 and 20pmol T-4. The reactions were
incubated at 65 C for 5min and allowed to cool to
37 C. To form HJT the separate forked duplex reactions
were combined, incubated at 37 C for 1h and cooled to
room temperature.
A portion of each HJ preparation (0.5ml) was removed
for use as a standard to determine the concentration of the
puriﬁed HJ preparations. The remainder was mixed with
16mlH 2O and 7.5ml 80% glycerol and loaded on an 8%
polyacrylamide gel. Voltage (150V) was applied for 1.5h
at 4 C. The HJ products were visualized by ﬂuorescence
on a Typhoon Imager (GE Healthcare), excised from the
gel and puriﬁed from the gel slice by electroelution for two
hours in a Model 422 Electroeluter (Bio-Rad, Hercules
CA). The eluant was concentrated in a Microcon YM-30
(Millipore, Billerica MA) and resuspended in 100mlo f
storage buﬀer (10mM Tris pH 7.5, 10mM MgCl2) and
stored at –20 C. Puriﬁcation quality and yields were deter-
mined by analysis on 8% native polyacrylamide gels,
followed by visualization and quantitation with
a Typhoon Imager and ImageQuant software (GE
Healthcare, Piscataway, NJ, USA).
Forked duplexes were prepared by annealing oligo-
nucleotides as described in Supplementary Table S1 in
1:1 molar ratios. Annealing reactions (50ml) were
incubated in 50mM LiCl2 and 0.71  PBS at 95 C for
5min and then allowed to cool to room temperature.
Helicase/exonuclease reactions
HJ substrates were reacted in standard reaction buﬀer
(40mM Tris pH 7.5, 4mM MgCl2, 5mM DTT, 0.1mg/
ml BSA and 2mM ATP) at 37 C for various time points
as indicated in the ﬁgure legends. The concentrations of
substrate and proteins WRN, X-WRN, TRF2, TRF2B
and RPA were as indicated in the ﬁgure legends.
Reactions were started by WRN or X-WRN addition,
and terminated by adding 2.7X stop dye [50mM
ethylenediaminetetraacetic acid (EDTA), 40% glycerol].
The reactions that included RPA and/or TRF2 were
Table 1. Holiday junction substrates used in this study
C
3„
C
T
5„
3„
T
5„
3„
T
C
A
5„
3„
C
5„
3„
HJA 
1, 2, 3, 4 
HJbio-center 
bio-1, 2, 3, 4 
HJbio-end 
1, 2, -3, -4bio 
HJT 
T-1, T-2, T-3, T-4 
HJM 
M-1, M-2, M-3, M-4 
A
A
T
5„
T=TAMRA; C=Cy5; A=Alexa488. Dotted lines denote an
oligonucleotide with an exonuclease-vulnerable 30-end lacking a
thiophosphate bond protection. Bolded lines indicate the G-rich
strand of telomeric repeats. Numbers under the name of the construct
denote the oligonucleotides used to create the construct (see
Supplementaary Table S1),
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EDTA, 1mg/ml proteinase K, 300mM LiCl, 1.5% SDS)
and incubated at 37 C for 30min. As SDS ﬂuoresces and
interferes with analysis of the ﬂuorescent substrates, it was
precipitated based on a protocol by Zhitkovich and Costa
(33). Brieﬂy, 4ml 1M KCl was added to the 31.5-ml
stopped reactions, followed by incubation on ice for
5min. The precipitate was pelleted by centrifugation for
10min at 10000g at 4 C. The supernatant (31ml) was
drawn oﬀ and transferred to a fresh tube with 15ml
of loading buﬀer (40% glycerol, 0.5  TE). The SDS
precipitation procedure did not result in any signiﬁ-
cant reannealing of the dissociated ssDNA products
(Supplementary Figure S1). The terminated reactions
were run on either 8% or 12% native polyacrylamide
gels as indicated in the ﬁgure legends at 150V.
The TAMRA, Cy5 and Alexa488 ﬂuorophores
were visualized on a Typhoon Imager using the preset
TAMRA, Cy5 and Alexa488 laser excitation and
emission settings, with a photomultiplier gain of 575V
for all channels and normal sensitivity. Control reactions
ensured that cross-talk between channels did not occur
(data not shown). Reaction substrates and products were
quantiﬁed using ImageQuant 5.1 (GE Life Sciences)
software. The local median analysis was used for back-
ground correction. Substrate and products were calculated
as the percent of the total DNA in each lane for each
ﬂuorophore. All values were corrected for background
in the no protein and boiled control lanes as described
previously (34).
Electrophoretic mobility shift assay
Binding reactions (10ml) contained standard reaction
buﬀer (40mM Tris pH 7.5, 4mM MgCl2, 5mM DTT,
0.1mg/ml BSA, 2mM ATP), 5% glycerol and 5nM
DNA substrate. The reactions were initiated by adding
various concentrations of TRF2, as indicated in the ﬁgure
legend, and were incubated for 20min at room tempera-
ture. The reactions were loaded on 1% agarose
gels and electrophoresed in 0.5  TBE at 4 C and 140V
for 1h. The ﬂuorescent products and substrates were
visualized and analyzed as described for the helicase
reactions.
RESULTS
WRN helicase and exonuclease activities simultaneously
process HJs
Prior to investigating TRF2 modulation of WRN activity
on HJ substrates, we required a more complete under-
standing of WRN mechanism for HJ dissociation.
Previous independent studies demonstrated WRN
exonuclease activity at the 30 blunt end of a static
four-way junction (27) and WRN helicase dissociation
of a four-way junction with a mobile homologous core
(11). Therefore, we asked whether both activities could
simultaneously process a model HJ with a mobile core.
To test this, we developed a multiplex ﬂuorophore
imaging method to track the fate of individual strands
of a four-way construct in which three strands were
labeled with a unique ﬂuorophore. Previous studies with
four-way junctions monitored substrate conversion
to ssDNA by tracking migration of one radiolabeled
strand in the construct. While current ﬂuorophores still
suﬀer the disadvantage of decreased sensitivity compared
to
32P radioactivity, they oﬀer the distinct advantage of
identifying the exact oligonucleotide composition of all
intermediates and products present in each band on a
gel. This is particularly critical if the HJ construct is asym-
metric due to the presence of telomeric repeats or chemi-
cally modiﬁed bases in some arms, as in many of the HJs
in this study (Table 1).
Each arm of the HJA construct (Table 1) is 25bp
long with a 12-nt homologous center (11). Since a
four-way junction is unlikely to have four exposed ends
in vivo, all the 30 ends except for the T-oligonucleotide
contained a thiophosphate bond to protect against
exonuclease activity. One exposed end mimics a regressed
replication fork which is thought to be a target for WRN
(5,28,35). WRN processing of the HJA substrate led to
a variety of displaced DNA products that were uniquely
identiﬁed by their ﬂuorescent tags (potential products
shown separately in Supplementary Figure S2). The
appearance of a forked duplex preceded the appearance
of ssDNA product (Figure 1A), as shown schematically in
Figure 1B. The distribution of the T-oligo, which con-
tains the unprotected 30end, among the various intermedi-
ates and products was quantitated (Figure 1C). In the
ﬁrst 8min of the reaction <5% of the HJ was unwound
and the predominant displaced T-oligo species was
an intact fork duplex (3% of the total DNA) [Figure 1A
(lanes 2–10) and C]. After 16min, both T-oligo
exonuclease degraded fork (exo-fork) and ssDNA
(exo-ssDNA) species began to predominate (8% and
3%, respectively), and increased linearly with time to
19% and 18%, respectively, at 60min (Figure 1C). After
60min the amount of intact T-oligo in a fork or as ssDNA
was low (<3%) or negligible, respectively, indicating
robust WRN exonuclease attack of the vulnerable arm
during the reaction (Figure 1D). Upon completion
the A-oligo, which pairs with both the T- and C-oligos
in the HJ, was evenly divided between an intact fork
with the C-oligo (8%) and a degraded fork with
the T-oligo (11%; Figure 1D). Similar amounts of fork
and ssDNA product were detected for each oligo,
indicating no apparent bias for dissociation of any
of the arms (Figure 1D). Our data are consistent with
a mechanism for HJ processing in which WRN
simultaneously displaces the HJ into forks while
degrading the vulnerable T-oligo, followed by fork dis-
placement to ssDNA.
WRN helicase initiates HJ strand displacement at the
center and translocates outward
WRN binds the HJ core and is presumed to initiate
unwinding from the center (28). However, while WRN
helicase is inactive on blunt ended dsDNA, the WRN
exonuclease can digest the blunt ends of substrates
that contain junctions such as forks, bubbles or HJs,
Nucleic Acids Research, 2010,Vol.38, No. 12 3987presumably by WRN ﬁrst loading at the junction site (28).
Therefore, it is formally possible that WRN helicase may
also initiate strand displacement from the blunt end of an
HJ, such as at a regressed replication fork, which may
bypass eﬀects of TRF2 bound at the core. To test the
mechanism of HJ unwinding we used strategically placed
biotin/streptavidin blocks. We and others showed
that while a biotin does not interfere with WRN helicase
activity (Supplementary Figure S1), a biotin/streptavidin
complex can inhibit strand displacement (12).
Control experiments conﬁrmed that a biotin/streptavidin
complex inhibits X-WRN unwinding of a forked duplex
only when present on the translocating strand
(Figure 2A), but not when present on the non-
translocating strand (Figure 2B). Slower migration of
the fork and ssDNA product upon streptavidin addition
conﬁrms the presence of a biotin/streptavidin complex.
An exonuclease-dead variant of WRN (X-WRN) was
used to examine helicase alone. Since WRN helicase is
poorly processive, RPA was required to increase product
yield for detection of potential inhibition, but did
not relieve the biotin/streptavidin block to WRN unwind-
ing and does not melt the duplex (Supplementary
Figure S3).
We reasoned that if WRN initiates unwinding from
the HJ center then a biotin/streptavidin block at the
core, 24nt from the 50-end of the T-oligo (HJbio-center),
would inhibit WRN 30–50 translocation on the T-oligo
through the T/A duplex arm (Figure 3A III, open
arrows). However, unwinding in the ‘vertical’ axis (dark
arrows) would be permitted (Figure 3A, dark arrows)
yielding products that included the T-oligo trapped in
a fork with the A-oligo. When HJbio-center was
incubated with X-WRN and RPA, 47% and 89% of the
T- and A-oligos were liberated as ssDNA, respectively
[Figure 3B and C (lane 2), and 3D]. Some of the T-oligo
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Figure 1. WRN helicase and exonuclease simultaneously process HJ substrates with a mobile core. (A) HJA (2nM) was incubated with 24nM
WRN in standard reaction buﬀer at 37 C. Aliquots were terminated at various times from 0.5 to 60min in 2-fold increments (lanes 2–10). Reactions
were run on a 12% native polyacrylamide gel and were visualized with a Typhoon Imager in the TAMRA (blue), Cy5 (green) and Alexa 488
(red) channels. Colors assigned by Imagequant software. The exonuclease degraded products are indicated as (a) = exo-fork and (b) = exo-ssDNA.
(B) Schematic of WRN strand displacement and exonuclease products. T=TAMRA, C=Cy5 and A=Alexa488 labeled oligonucleotides.
The 30 end of the exonuclease vulnerable T-oligo is highlight as a dotted line. (C) The percent of displaced T-oligo products from the reactions
in (A) were quantitated as described in ‘Materials and Methods’ section and plotted against time. Intact fork, solid black line and
squares; exonuclease-degraded fork, dashed black line and triangles; intact ssDNA, solid gray line and squares; exonuclease-degraded ssDNA,
dashed gray line and triangles. (D) Substrate and product distribution for each labeled oligonucleotide in the HJ construct after 1h reaction.
The percent of T-, A- and C-oligos present in the HJ substrate and each intermediate and product were quantitated as a function of
total oligonucleotide as described in ‘Materials and Methods’. Values represent the mean and standard deviation of two or three separate
experiments.
3988 Nucleic Acids Research, 2010,Vol.38, No. 12was released as a fork with the unlabeled oligo, but
not with the A-oligo, perhaps due to greater G/C
content on the HJ arm composed of the T-oligo
and the unlabeled strand (Supplementary Table S1).
Upon streptavidin addition, the displaced ssDNA
product decreased substantially to 17% and 55% for the
T- and A-oligos, respectively [Figure 3B and 3C (lane 5),
and 3D]. Importantly, streptavidin addition yielded a
novel forked species consisting of the T- and A-oligos
(total of 31% and 15%, respectively, since a T/unlabeled
fork is also present) and a novel triple stranded species
consisting of the T- and A-oligos (17% and 15%, respec-
tively) bound to the unlabeled oligo. These species
contained negligible amounts of C-oligo (1%) (data not
shown) and the three-way probably resulted from shifting
between two conformations (Figure 3E). The 12-nt
homologous core can shift the biotin/streptavidin block
from the T/A duplex arm (Figure 3A, I and II) to the
T/unlabeled duplex arm (Figure 3A, III), whereas
the C-oligo is never present in a duplex arm with
a biotin (Figure 3A). These dynamic conformations
likely explain the lack of complete WRN inhibition
and the generation of a novel three-way species by a
biotin/streptavidin barrier at the HJ core.
To test whether WRN can load on the HJ
blunt end and translocate toward the center while
unwinding, we asked if a 30 biotin/streptavidin complex
on the A-oligo would inhibit WRN helicase activity
(HJbio-end) (Figure 4A). In contrast to HJbio-center,
streptavidin addition to HJbio-end did not alter strand
displacement by X-WRN and RPA. Approximately
95% of the A-oligo was displaced as ssDNA in the
absence or presence of streptavidin (Figure 4A, lanes
2–4 or 7, respectively), and the three-way product
observed in the HJbio-center reactions was not
apparent. Furthermore, RPA alone does not melt the
X-WRN
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Figure 2. A biotin–streptavidin complex on the translocating strand of a forked duplex inhibits WRN unwinding activity. Reactions contained a
31-bp forked duplex (0.5nM) with a biotinylated nucleotide (inverted trapezoid) on the WRN translocating (A) or nontranslocating strand (B). Black
box denotes streptavidin. The forks were constructed by annealing oligonucleotides bio-1 and 4 (A) or bio-1 and 2 (B) (Supplementary Table S1).
T=TAMRA; A=Alexa488. The duplex length (bp) on either side of the biotinylated nucleotide is shown. The substrate was pre-incubated with
either 0 (lanes 1 and 2) or 30nM (lanes 3 and 4) streptavidin in standard reaction buﬀer prior to adding 3.4nM X-WRN and 12nM RPA. Reactions
were for 20min at 37 C, and were run on an 8% native polyacrylamide gel for 2.5h and visualized with a Typhoon imager. A streptavidin-bound
T-oligo was loaded (lane 6) as a marker and the boiled substrate lane is indicated with a triangle (lane 5). The gel scans show the TAMRA emission
channel. (C) Quantitation of the ssDNA product. The percent of ssDNA T-oligo product was quantitated as described in ‘Materials and Methods’
section. Values represent the mean and SEM. from two independent experiments.
Nucleic Acids Research, 2010,Vol.38, No. 12 3989HJ (Supplementary Figure S3). These data indicate that
a biotin/streptavidin complex at the HJ core, but not at
the HJ blunt end, inhibits WRN strand displacement.
TRF2 protects telomeric arm HJ DNA from WRN
strand displacement activity
We hypothesized that TRF2 protects HJs from WRN
activity since it stabilizes HR-like structures in the
telomere from unwanted processing in vivo (7). To test
this we examined the non-telomeric HJA, and designed
an HJ containing three telomeric repeats in two duplex
arms in a trans conﬁguration (HJT; Table 1). A fully
telomeric HJ construct would have been unstable
due to spontaneous branch migration. TRF2 pre-binding
to the substrate decreased the percent of WRN
HJT strand displacement in a dose-dependent
manner from 49% to 20% (Figure 5A and D). A
TRF2-mediated decrease in exonuclease-degraded
products was also observed (Alexa 488 channel, data
not shown; TAMRA channel, Supplementary Figure
S4). To determine whether TRF2 binding to the HJ
core via its B-domain was responsible for WRN
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Figure 3. A biotin–streptavidin complex at the HJ core impedes WRN helicase activity. (A) The HJbio-center construct has a 12-nt homologous
core that permits branch migration. The center construct (II) shows the HJ in a symmetric conformation with 25-bp arms. The left and right con-
structs (I and III) show the possible extreme conformations. T=TAMRA; C=Cy5; A=Alexa488; inverted trapezoid denotes a biotin
moiety. Black box denotes a streptavidin. The predicated possible directions of unwinding are shown for each conformation;
white arrow denotes unwinding along the horizontal axis; black arrow denotes unwinding along the vertical axis. (B and C) The HJbio-center
substrate (0.5nM) was pre-incubated without (lanes 1 and 2) or with (lanes 4 and 5) 30nM streptavidin under standard reaction conditions
prior the addition of 15nM X-WRN and 45nM RPA. The reactions were conducted for 1h at 37 C. The products were run on an 8% native
acrylamide gel for 2.5h and visualized with a Typhoon Imager. Black triangle denotes boiled substrate lane. The TAMRA and Alexa488 emission
channels are shown in (B) and (C), respectively. (D) Quantitation of ssDNA reaction products. The percent of T-oligo (gray bars) and A-oligo (white
bars) detected as ssDNA product was quantitated as described in ‘Materials and Methods’ section. The values represent the mean and standard
deviation from two to four independent experiments. (E) Schematic of the three-way product species that are generated upon addition of
streptavidin.
3990 Nucleic Acids Research, 2010,Vol.38, No. 12inhibition, we tested the non-telomeric HJA which lacks
Myb binding sequences. In sharp contrast to the
telomeric arm HJT, pre-binding TRF2 to HJA did not
alter WRN unwinding (Figure 5B and D).
Next, we asked whether TRF2 interaction with the
HJ arms via the Myb domain was responsible for TRF2
inhibition of WRN activity on the telomeric HJT. To
test this, a TRF2 fragment with the N-terminal B
domain deleted (TRF2B) was used. The pre-incubation
of telomeric HJT with TRF2B exhibited no protec-
tive eﬀect against WRN strand displacement activity
(Figure 5C and D), nor did it alter the amount
of exonuclease-degraded T-oligo (data not shown).
These experiments indicate that TRF2 protects telomeric
HJ DNA from WRN activity, but only on substrates con-
taining binding sites for both the TRF2 B and Myb
domains.
A previous study reported that TRF2 protects an
HJ with two telomeric repeats in the center from
cleavage by HJ resolvase enzymes (24). We tested the iden-
tical construct (HJM, Table 1) to determine whether
TRF2 could provide a comparable protection from
WRN strand displacement. While HJM has binding
sites for both the TRF2 Myb and B domains, the
Myb domain can only bind when the homologous core
migrates to an extreme conformation with the two
telomeric repeats in tandem on the same duplex arm
(Figure 6A). In contrast to telomeric arm HJT, the
pre-incubation of telomeric core HJM with increasing
TRF2 concentrations did not alter the WRN strand dis-
placement or exonuclease products (Figure 6B and D).
To determine whether the lack of TRF2 inhibition
resulted from WRN digestion into the Myb binding
sequences, we repeated the experiment with the
exonuclease-dead X-WRN. However, TRF2 did not
alter X-WRN strand displacement of HJM either
(Figure 6C and D).
RAP1 does not alter TRF2 protection of telomeric arm
HJ from WRN activity
RAP1 is a member of the shelterin complex that binds
TRF2, and is required along with TRF2 to protect
telomeric ends from non-homologous end joining
(NHEJ) (36,32). Therefore, we asked if RAP1 also
cooperates with TRF2 to prevent telomeric HJ displace-
ment. To test this, we pre-bound telomeric arm
HJT with 25nM TRF2 and increasing RAP1 concen-
trations (0–50nM) prior to WRN addition (Figure 7B,
lanes 2–5). While TRF2 inhibition of WRN was
apparent, no signiﬁcant diﬀerence in the amount of
displaced HJ DNA was observed as a function of RAP1
concentration (Figure 7C). Nor did we detect any modu-
lation of WRN activity by RAP1 (50nM) alone
(Figure 7B, lane 6).
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Figure 4. A biotin–streptavidin complex at the 30-end of an HJ arm does not alter WRN helicase activity. The HJbio-end substrate has a biotin tag
at the 30-end of the A-oligo. T=TAMRA; C=Cy5; A=Alexa488; inverted trapezoid denotes a biotin moiety. Black box denotes streptavidin.
(A) The HJbio-end (0.5nM) substrate was pre-incubated without (lanes 2–4) or with (lanes 6 and 7) 30nM streptavidin under standard reaction
conditions prior the addition of 15nM X-WRN and 45nM RPA. The reactions were conducted for 1h at 37 C. The products were run on an 8%
native acrylamide gel for 2.5h and visualized with a Typhoon Imager. Black triangle denotes boiled lane. M denotes an A-oligo ssDNA marker
bound by streptavidin. The Alexa488 emission channel is shown. (B) Quantitation of ssDNA reaction products. The percent A-oligo detected as
ssDNA product was quantitated as described in ‘Materials and Methods’ section. The values represent the mean and standard deviation from three
independent experiments.
Nucleic Acids Research, 2010,Vol.38, No. 12 3991TRF2 exhibits increased binding to telomeric HJ
compared to non-telomeric HJ
We hypothesized that the mechanism by which TRF2
protects HJ DNA from WRN activity is via binding
both the HJ core and the telomeric repeats in the HJ
arms. Therefore, we predicted that TRF2 should exhibit
increased binding to a telomeric HJ, compared to a
non-telomeric HJ, since both TRF2 B and Myb domains
can engage the telomeric HJ. We performed
electrophoretic mobility shift assays to compare TRF2
binding to non-telomeric HJA and telomeric HJT and
HJM. The migration of all three substrates was retarded
by TRF2 in a protein concentration-dependent manner
(Figure 8A, lanes 1–15). TRF2 shifted HJT to a higher
migrating species compared to HJA or HJM, suggesting
that more TRF2 molecules may be bound to the telomeric
arm HJT substrate (Figure 8A, lanes 5, 10 and 15). A
shifted HJ/TRF2 complex was apparent at 50nM TRF2
for HJT and HJM, but was not detected until 125nM
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Figure 5. TRF2 inhibits WRN unwinding of HJ substrates with telomeric arms. A schematic of the telomeric arm (HJT) and non-telomeric
HJA constructs are shown in (A–C). Thick black lines denote (TTAGGG)3 repeats. T=TAMRA; C=Cy5; A=Alexa488. The 30-end of
the exonuclease-vulnerable T-oligo is highlighted as a dotted line. Predicted TRF2 binding sites are indicated with the circle (B-domain) and the
ellipse (Myb domain). The substrates (0.5nM) HJT (A) or HJA (B) were pre-incubated with 0, 0.5, 5, 12.5 or 25nM TRF2 [(A), lanes 2–6,
respectively] and 0, 0.5, 5 or 25nM TRF2 [(B), lanes 1–4] in standard reaction buﬀer. The reactions were initiated by the addition of 19nM
WRN and reacted for 1h at 37 C. The reactions were run on 8% native gels for 1.5h and visualized with a Typhoon Imager. Scans of the
Cy5 emission channel are shown in (A) and (B). Triangle indicates boiled substrate; M denotes a marker lane; arrows denote a triple-stranded
species. (C) TRF2B does not alter WRN unwinding of the telomeric HJ. The HJT (0.5nM) substrate was pre-incubated with 0, 0.5, 5 or
25nM TRF2B (lanes 2–5) prior to the addition of 19nM WRN. Reactions were for 1h at 37 C, and were run on an 8% native gel. The scan
from the Cy5 emission channel is shown. (D) Quantitation of HJ unwinding. The percent of C-oligo present in the HJ substrate was quantitated as a
function of total C-oligo DNA in the reaction as described in ‘Materials and Methods’ section and plotted against TRF2 or TRF2B concentration.
The values represent the mean and standard deviation from at least three independent experiments.
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Nucleic Acids Research, 2010,Vol.38, No. 12 3993TRF2 for HJA (Figure 8A, lanes 3, 8 and 13). The binding
curves for the HJT and -M substrates showed a 50% shift
by about 50nM TRF2, compared to  100nM for HJA
(Figure 8C).
Next, we tested whether the lack of TRF2B inhibition
of WRN on the HJT substrate resulted from a failure
of the protein to bind the telomeric arms. The
incubation of increasing TRF2B concentrations
with the non-telomeric HJA did not detectably alter
substrate migration (Figure 7B, lanes 6–10), as expected,
since this fragment lacks the B domain. In contrast, HJT
migration was noticeably retarded at 125 and 250nM
TRF2B concentrations (Figure 7B, lanes 4 and 5),
with 54% and 74% of the HJT substrate shifted, respec-
tively (Figure 7C). The TRF2 Myb domain can only bind
a subset of HJM conformations (Figure 6A), thus, the
percent of TRF2B bound substrate was decreased
compared to HJT (Figure 8C). In summary, these
data indicate that TRF2 exhibits increased binding to
telomeric versus non-telomeric HJs and shifts HJ
DNA with telomeric arms (HJT) to higher migrating
species compared to HJ DNA with a telomeric
core (HJM).
DISCUSSION
The WRN helicase/exonuclease protein is a RecQ family
helicase that displaces HJ DNA, consistent with a cellular
function in restoring stalled replication forks and disrupt-
ing homologous recombination intermediates (1,2,4,6).
Previous studies showed that TRF2 protects telomeric
HJ DNA at the t-loop/D-loop from cleavage by
endonucleases in vivo (16,25) and in vitro (24), but TRF2
protection from HJ displacement was not previously
reported. Our results showed that TRF2 protects HJ
DNA from WRN-mediated strand displacement, but
only if TRF2 can simultaneously bind the HJ with both
of its DNA-binding domains: (i) the B domain which
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were loaded on a 1% 0.5  TBE agarose gel and electrophoresed for 1h at 140V in 4 C. Gels were scanned on a Typhoon Imager and visualized in
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3994 Nucleic Acids Research, 2010,Vol.38, No. 12binds HJ DNA regardless of sequence and (ii) the Myb
domain which binds telomeric duplex DNA (21,22). This
is in contrast to previous research which showed that the
B-domain is suﬃcient for protecting HJ DNA from enzy-
matic cleavage (24).
WRN mechanism of HJ strand displacement
The novel multiplex imaging of HJ strands in this study
allowed us to elucidate mechanistic details of WRN strand
displacement that would not be possible by labeling one
strand of the construct as done previously. Our data are
consistent with a mechanism by which WRN displaces
HJs starting from the HJ center and processing outward.
Speciﬁcally, on our substrate we propose WRN
translocates 30 to 50 along the T-oligo from the center
toward the 50 TAMRA label at the blunt end (Figure 3).
The ﬁrst evidence was that a biotin–streptavidin barrier
placed on the T-oligo at the HJ core led to a 2-fold reduc-
tion in single-stranded A- and T-oligo products (Figure 3).
Second, the barrier at the HJ core also induced some
trapping of the A- and T-oligos into novel two-way and
three-way products that lacked the C-oligo (Figure 3)
after WRN unwinding. This suggests that the biotin–
streptavidin barrier inhibits WRN processivity along the
A-T arm (Figure 3E, I) and the T-unlabeled arm
(Figure 3E, III) depending on the barrier location in the
speciﬁc mobile core conformation, but not along the
C-oligo arms which never contains the barrier in any
core conformation. Third, if WRN helicase initiated
unwinding from an HJ arm blunt end and moved
inward, then a barrier on the 30-end of a strand should
block WRN helicase. However, such a barrier had no
eﬀect on strand displacement, nor did it lead to novel
‘trapped’ products (Figure 4). In summary, although the
WRN exonuclease can initiate at an HJ blunt end
(Figure 1), the helicase does not, and thus, could not eﬃ-
ciently circumvent a protein bound to the HJ core such
as TRF2.
Our results with the HJ barrier containing constructs
corroborate electron micrographs showing WRN bound
to the HJ center (28) and a protein–DNA cocrystal of
RecG bound to a model replication fork (37). RecG and
WRN belong to the SF2 superfamily of helicases (38), and
RecG converts HJs into forked substrates and then into
ssDNA similar to WRN (39,11) (Figure 1). The crystal
structure shows a RecG monomer bound to the junction
of a model replication fork (37), which resembles the
junction of a regressed replication fork or HJ.
Mechanism of TRF2 inhibition of WRN telomeric arm
HJ strand displacement
Our data help resolve a paradox of TRF2-WRN interac-
tions. WRN is required for telomere preservation (8,40)
and TRF2 stimulates WRN helicase on forked sub-
strates (30), yet TRF2 prevents WRN promotion of aber-
rant telomere t-loop/D-loop HR cleavage (25). The
WRN requirement for telomeric circle formation when
the TRF2B mutant is overexpressed (25) suggests
TRF2 inhibits WRN-mediated branch migration at the
telomere t-loop/D-loop. Here we report that TRF2
modulation of WRN activity is highly substrate depen-
dent. At a 50:1 TRF2:HJ molar ratio, prebound TRF2
inhibited WRN strand displacement of an HJ with two
telomeric arms by 50%, but unwinding of the
non-telomeric HJ was unaﬀected (Figure 5). At this
same ratio, nearly 100% of both the telomeric arm and
non-telomeric HJs are bound by TRF2 (Figure 8), consis-
tent with previous studies (21). This shows that TRF2
substrate binding via the B domain only (non-telomeric
HJ) provides no protection against WRN activity (Figure
5). Consistent with this, the TRF2 Myb domain alone
cannot protect the telomeric arm HJ (Figure 5C) or a
telomeric fork (30) (the B-domain does not bind a fork),
from WRN activity.
The mechanism of TRF2 protection against HJ
cleavage diﬀers from protection against WRN HJ strand
displacement. A previous study showed that a 40:1
TRF2:HJ ratio reduced enzymatic HJ cleavage by 80%
on an HJ with two telomeric repeats in the mobile
center, and that protection was primarily via the
B domain (24). With this same substrate (HJM,
Figure 6A) even a 50:1 molar ratio of TRF2 to HJ
provided no protection against WRN helicase activity
(Figure 6B). One explanation for this diﬀerence is that
while this HJ has binding sites for both the TRF2 B and
Myb domains, both probably cannot bind at once. The
footprint of a single Myb domain is YTAGGGTTR (41);
thus, a TRF2 homodimer cannot bind this substrate with
both Myb domains at once. A single Myb domain can
bind only if the HJ mobile core has migrated to one
extreme (Figure 6A), but it may not be sterically
possible for the B domain to bind as well. Consistent
with this, when the HJ-speciﬁc TRF2 B-domain was
deleted the percent of TRF2 bound telomeric core HJM
was half that of telomeric arm HJT (Figure 8C).
Protection against WRN helicase activity requires both
TRF2 domains to be bound, not just the B-domain as is
the case with protection against cleavage. Poulet and col-
leagues (24) reported that the TRF2 B-domain ‘melts’ the
mobile center of the HJ, creating an altered conformation
that HJ cleaving enzymes cannot recognize. A melted HJ
center would hardly discourage a helicase, particularly one
that initiates displacement at the HJ center, such as WRN
(Figures 3 and 4).
Several potential models might explain the TRF2 inhi-
bition of WRN activity on telomeric arm HJ. In stark
contrast to a biotin–streptavidin complex at the HJ core
(Figure 3), a core bound TRF2 B-domain does not inhibit
WRN (Figure 5), which rules out a TRF2 steric inhibition
model. Since TRF2 interacts with WRN via the B-domain
(25), we would have expected inhibition on a non-
telomeric HJ, which was not the case (Figure 5B). Thus,
TRF2 inhibition of WRN telomeric HJ activity is unlikely
to be mediated by protein–protein interactions, which
is the proposed mechanism for p53 inhibition of WRN
HJ activity (42). Instead, we favor a model whereby
both TRF2 DNA-binding domains must bind the HJ
simultaneously in order to ‘lock down’ the substrate into
a conformation that is unfavorable for WRN strand
displacement or branch migration activity. While HJ con-
structs are often depicted as square-planar shapes,
Nucleic Acids Research, 2010,Vol.38, No. 12 3995crystallographic evidence indicates that duplex arms can
stack on one other (43). Single-pair ﬂuorescence resonance
energy transfer (FRET) and structural studies showed that
HJ DNA alternates between the stacked conformation
and an open square-planar conformation, which is the
form that branch migrates and is favored by proteins
that promote HJ migration (37,44–46). Simultaneous
interaction of TRF2 with the core and the telomeric
arms might promote the stacked arm conformation,
perhaps via TRF2 molecules bound to separate arms inter-
acting with each other through dimerization or higher
oligomeric forms. Consistent with this, the telomeric arm
HJ (HJT) exhibited a slower TRF2-bound migrating
species than either the non-telomeric (HJA) or telomeric
core HJ (HJM) (Figure 8A), which likely reﬂects a larger
oligomeric complex. Our results agree with previous
studies that show TRF2 has higher aﬃnity for HJs with
telomeric repeats, compared to non-telomeric HJs (24).
Therefore, the number of accessible telomeric binding
sites is important for TRF2 HJ binding, and this correlates
with protection from WRN activity. We suggest that a
fully telomeric HJ would enjoy greater TRF2 protection
since there are far more TRF2 binding sites compared to
our hybrid constructs.
Role for RAP1/TRF2 complex in protection against HJ
displacement
The current study extends our understanding of WRN
function in the context of the mechanism of action of
shelterin proteins at telomeres. While RAP1 forms a
complex with TRF2 and is necessary to protect telomere
ends from NHEJ (32), it does not alter TRF2-mediated
inhibition of WRN on an HJ containing telomeric arms
(Figure 7). RAP1 binds to the central TRF2 dimerization
domain (36), whereas WRN interacts with the TRF2
N-terminal B domain (25). Thus, our biochemical data
are consistent with cellular studies since RAP1 should
still localize to telomeres with TRF2B expression but
oﬀers no protection against aberrant HJ cleavage (25),
and RAP1 does not localize to telomeres in the absence
of TRF2 when protection against aberrant NHEJ is
lost (47). Neither does RAP1 increase the binding
aﬃnity of TRF2 for telomeric DNA (48). Therefore,
RAP1-mediated protection against NHEJ probably has
no mechanistic basis in protection against WRN activity.
The yin and yang of WRN at telomeres
Telomeres are dynamic structures regulated by the inter-
play of multiple proteins composing both the shelterin
complex and the numerous proteins that interact with
shelterin. Many of these proteins become deleterious
for telomere maintenance if dysregulated (7,49). WRN
is necessary to prevent telomeric circle formation in
telomerase-positive cells, but without full-length TRF2,
WRN itself is required for telomere circle formation
(25). In yeast, the TRF2 ortholog Taz1 similarly protects
against telomere loss mediated by the WRN ortholog
Rqh1 (50) in conjunction with the RPA ortholog Rad11
(51). Telomere preservation is restored in Taz1 mutants by
either mutating a SUMOylation site on the Rgh1 protein
(50) or by overexpressing the shelterin protein POT1 (51).
By demonstrating that TRF2 can protect telomeric HJ
DNA from WRN activity, our study provides a mecha-
nistic basis for the cellular studies showing that TRF2 or
Taz1 regulate WRN or Rqh1 activity, respectively.
In summary, we veriﬁed that WRN displaces HJs from
the center and progresses outward, and that this strand
displacement occurs simultaneously with WRN
exonuclease activity. We found that TRF2 can protect
telomeric HJs from WRN activity only if both TRF2
DNA-binding domains simultaneously engage the HJ
core and the arms. Our biochemical studies provide an
explanation for the cellular studies that indicate WRN
adversely aﬀects telomere processing in the absence of
TRF2 (25). Understanding how shelterin accessory
factors, such as WRN, are regulated by speciﬁc shelterin
proteins is critical for deﬁning mechanism of telomere loss
and preservation, and the consequences of dysregulation
for human disease.
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